-
Archives
- June 2021
- February 2020
- August 2018
- July 2018
- June 2018
- July 2017
- May 2017
- January 2017
- October 2016
- June 2016
- March 2016
- January 2016
- November 2015
- August 2015
- July 2015
- June 2015
- May 2015
- June 2014
- May 2014
- April 2014
- December 2012
- September 2012
- July 2012
- May 2012
- April 2012
- February 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
-
Meta
Category Archives: PET Drugs
NRC Licensing Guidance for Eckert and Ziegler Ge-68/Ga-68 Generator
On September 28, 2016, the U.S. Nuclear Regulatory Commission published Licensing Guidance for Eckert and Ziegler GalliaPharm Germanium-68/Gallium-68 Pharmacy Grade Generator. All sections of this guidance apply to both medical licensee and commercial nuclear pharmacy licensee use of this generator … Continue reading
Posted in PET Drugs
Leave a comment
Sponsored Session from SNMMI Annual Meeting:PET Drug Manufacturing: Living in an FDA-Regulated World
The Coalition for PET Drugs recently sponsored a session focused on FDA topics relevant to PET drug manufacturers. The session was held at the 2016 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in San Diego. … Continue reading
Posted in PET Drugs
Leave a comment
Coalition Comments on PET GMP Recordkeeping Burden
On February 29, 2016, the Coalition submitted comments to the FDA on the burdens associated with the PET drug Good Manufacturing Practice (GMP) regulations at 21 CFR part 212. As previously reported, the FDA issued a Federal Notice on December … Continue reading
Posted in PET Drugs
Leave a comment
Public Comments for PET GMP Recordkeeping Burden
The Coalition would like to make PET drug manufacturers aware of an announcement from the FDA that appeared in the December 29, 2015, issue of the Federal Register. The notice announces the opportunity for public comment on the annual recordkeeping … Continue reading
Posted in PET Drugs
Leave a comment
USP Seeking Comments on General Chapter Revisions. Deadline approaching!
The US Pharmacopeia (USP) is currently in the process of revising several general chapters that are important to the nuclear medicine community. The USP sets public standards that serve patients, academia, industry, regulators, healthcare professionals, and other stakeholders. As a … Continue reading
Posted in PET Drugs
Leave a comment
Reminder: Two-year post approval inspections
The Coalition would like to share some important reminders with PET Drug manufacturers that may be coming up on their two-year post approval inspection. Below is a list of items FDA inspectors recently asked for in one of the current … Continue reading
Posted in PET Drugs
Leave a comment
Important Change to NDA 021870
The Coalition would like to make PET drug manufacturers aware of a change to an FDA-approved application for Fludeoxyglucose F 18 Injection (FDG). This modification involves the radioactivity concentration (strength) for FDG described in new drug application (NDA) 021870, which … Continue reading
Posted in PET Drugs
Leave a comment
Coalition Comments on Generic Drug User Fee Act
The Coalition for PET Drugs submitted comments to the U.S. Food and Drug Administration (FDA) on the reauthorization of Generic Drug User Fee Act (GDUFA). In general, the Coalition supports GDUFA and believes that user fees have successfully provided the … Continue reading
Posted in PET Drugs
Leave a comment
Slide Presentations from “FDA: Imaging Drug Development – Regulatory Issues” CE Session
The Coalition is following up on a message that we posted on May 29. In that posting, we highlighted a session at the recent SNMMI annual meeting entitled “FDA: Imaging Drug Development – Regulatory Issues.” The session was sponsored by … Continue reading
Posted in PET Drugs
Leave a comment
Sponsored Session from SNMMI Annual Meeting: Current Topics in FDA Reviews and Inspections of PET Drug Manufacturers
As we have done in past years, the Coalition for PET Drug Approval recently sponsored a session focused on FDA topics for PET drug manufacturers. The session was held at the 2015 annual meeting of the Society of Nuclear Medicine … Continue reading
Posted in PET Drugs
Leave a comment